Psychiatry and Neurology, Neurology · Omaha, NE
NPI
1427222959
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4242 Farnam St, Suite 500
Omaha, NE, 68131
Phone (402) 552-2650
Groups this clinician bills Medicare through
Medicare paid, 2024
$188K
32,320 services
Medicare patients, 2024
152
Average age 68
Drug cost, 2024
$1.1M
3,270 prescriptions
Company payments, 2025
$97K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chad A Whyte was code J0585 (injection, onabotulinumtoxina, 1 unit), 31,800 times for 61 patients. In total Chad A Whyte billed 32,320 services in 11 codes, and Medicare paid $188K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-12-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 31,800 | 61 | $4.73 | $151K |
| 99213 Office E&M - Established | Office | 173 | 95 | $57.20 | $9,896 |
| 64615 Musculoskeletal | Office | 160 | 61 | $90.23 | $14K |
| 99214 Office E&M - Established | Office | 107 | 79 | $84.08 | $8,997 |
| 99205 Office E&M - New | Office | 19 | 19 | $146.70 | $2,787 |
By year: 2022 $196K for 33,179 services; 2023 $193K for 33,172 services; 2024 $188K for 32,320 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chad A Whyte prescribed most often to Medicare patients was Sumatriptan Succinate, with 285 prescriptions and refills. In total Chad A Whyte wrote 3,270 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sumatriptan Succinate Generic | 285 | 302 | 50 | $16K |
| Gabapentin Generic | 160 | 235 | 41 | $2,634 |
| Naltrexone Hcl Generic | 144 | 156 | 51 | $5,329 |
| Qulipta Atogepant | 126 | 132 | 20 | $150K |
| Aimovig Autoinjector Erenumab-Aooe | 119 | 121 | 18 | $90K |
| Rizatriptan Rizatriptan Benzoate | 116 | 125 | 23 | $5,334 |
| Nurtec Odt Rimegepant Sulfate | 114 | 115 | 18 | $169K |
| Divalproex Sodium Er Divalproex Sodium | 103 | 167 | 26 | $2,121 |
| Topiramate Generic | 99 | 193 | 26 | $643 |
| Ubrelvy Ubrogepant | 88 | 88 | 20 | $113K |
| Trazodone Hcl Generic | 83 | 214 | 27 | $469 |
| Mirtazapine Generic | 71 | 95 | 16 | $717 |
| Methocarbamol Generic | 71 | 79 | 18 | $1,632 |
| Baclofen Generic | 59 | 89 | 12 | $875 |
| Tizanidine Hcl Generic | 57 | 81 | 14 | $753 |
Brand drugs: 726 claims; generic drugs: 2,544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chad A Whyte $97K ($97K in general payments such as food, travel and fees) from 31 companies. The largest payer was Abbvie Inc. with $45K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 71 | $45K |
| Axsome Therapeutics, Inc. AXSM | 34 | $26K |
| Lundbeck LLC | 30 | $13K |
| Pfizer Inc. PFE | 23 | $11K |
| Teva Pharmaceuticals USA, Inc. TEVA | 34 | $324 |
| Novartis Pharmaceuticals Corporation NVS | 20 | $262 |
| UCB, Inc. UCB.BR | 29 | $248 |
| Neurocrine BioSciences, Inc. NBIX | 13 | $193 |
| Merz Pharmaceuticals, LLC | 8 | $147 |
| Argenx US, Inc. ARGX | 5 | $129 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.